Brepocitinib for Noninfectious Posterior Uveitis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Texas Retina Associates, Plano, TX
Noninfectious Posterior Uveitis+7 More
Brepocitinib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).

Eligible Conditions

  • Noninfectious Posterior Uveitis
  • Non-infectious Pan Uveitis
  • Non-infectious Intermediate Uveitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Noninfectious Posterior Uveitis

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Screening up to 28 days after the last dose of study drug at 52 weeks

24 weeks
Proportion of participants meeting treatment failure criteria on or after Week 6 up to Week 24
Week 52
Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Noninfectious Posterior Uveitis

Trial Design

2 Treatment Groups

Brepocitinib Dose Level 1 PO QD
1 of 2
Brepocitinib Dose Level 2 PO QD
1 of 2
Experimental Treatment

24 Total Participants · 2 Treatment Groups

Primary Treatment: Brepocitinib · No Placebo Group · Phase 2

Brepocitinib Dose Level 1 PO QD
Drug
Experimental Group · 1 Intervention: Brepocitinib · Intervention Types: Drug
Brepocitinib Dose Level 2 PO QD
Drug
Experimental Group · 1 Intervention: Brepocitinib · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: screening up to 28 days after the last dose of study drug at 52 weeks
Closest Location: Texas Retina Associates · Plano, TX
2006First Recorded Clinical Trial
1 TrialsResearching Noninfectious Posterior Uveitis
76 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are receiving ongoing (or initiated during screening) therapy with oral prednisone.
You have non-infectious uveitis.
You are receiving up to one non-corticosteroid, non-biologic, immunomodulatory therapy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.